BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29181304)

  • 1. DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.
    Dong LL; Tang R; Zhai YJ; Malla T; Hu K
    Int J Ophthalmol; 2017; 10(11):1633-1639. PubMed ID: 29181304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with dendritic cell-based DNA vaccine pRSC-NLDC145.gD-IL21 protects mice against herpes simplex virus keratitis.
    Tang R; Zhai Y; Dong L; Malla T; Hu K
    Immunotherapy; 2018 Mar; 10(3):189-200. PubMed ID: 29370719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
    Hu K; He X; Yu F; Yuan X; Hu W; Liu C; Zhao F; Dou J
    Immunol Invest; 2011; 40(3):265-78. PubMed ID: 21204603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.
    Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N
    Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections.
    Hu K; Malla T; Zhai Y; Dong L; Tang R
    Ophthalmic Res; 2015; 55(2):99-110. PubMed ID: 26650397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis.
    Inoue T; Inoue Y; Hayashi K; Shimomura Y; Fujisawa Y; Aono A; Tano Y
    Cornea; 2002 Oct; 21(7 Suppl):S79-85. PubMed ID: 12484704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of immunization with herpes simplex virus glycoprotein D fused with interluekin-2 against murine herpetic keratitis].
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
    Nippon Ganka Gakkai Zasshi; 2001 Apr; 105(4):223-9. PubMed ID: 11329945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells.
    Jayaraman S; Heiligenhaus A; Rodriguez A; Soukiasian S; Dorf ME; Foster CS
    J Immunol; 1993 Nov; 151(10):5777-89. PubMed ID: 8228262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis.
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
    Jpn J Ophthalmol; 2002; 46(4):370-76. PubMed ID: 12225814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diagnostic method for herpes simplex keratitis by simultaneous measurement of viral DNA and virus-specific secretory IgA in tears: an evaluation.
    Shoji J; Sakimoto T; Inada N; Kamei Y; Matsubara M; Takamura E; Sawa M
    Jpn J Ophthalmol; 2016 Jul; 60(4):294-301. PubMed ID: 27126382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
    Frye TD; Chiou HC; Hull BE; Bigley NJ
    Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.
    Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T
    Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.